In patients with heart failure (HF) and reduced left ventricular ejection fraction, guideline-directed medical therapy improves survival. For advanced HF refractory to medical and device therapies, durable left ventricular assist device (LVAD) implantation is indicated. Although LVADs provide substantial left ven...
T. Kondo, S. Kazama, T. Imaizumi et al.· European Heart Journal· 0 citations
BACKGROUND
The nationwide impact in Japan of contemporary improvement in the clinical management of durable left ventricular assist device (LVAD), together with the introduction of the HeartMate 3 (Abbott, Pleasanton, CA, USA), on clinical outcomes remains uncertain.
METHODS AND RESULTS
Using the Japanese Registry fo...
Teruhiko Imamura, K. Kinugawa, Takashi Nishimura et al.· Circulation Journal· 0 citations
BACKGROUND
Durable left ventricular assist devices (LVADs) improve the outcomes of patients with advanced heart failure; however, recurrent hospitalization remains a major burden. The days alive and out of hospital (DAOH) is a patient-centered metric that reflects both survival and hospitalization burden; however, data...
Toru Kondo, S. Kazama, Takahiro Imaizumi et al.· Journal of the American Hear...· 0 citations
This nationwide real-world study provides the first validation of a nationally mandated DT eligibility algorithm and may support risk-based clinical decision-making in Japanese DT practice.
Teruhiko Imamura, K. Kinugawa, Takashi Nishimura et al.· JACC: Asia· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.